# US 2023/0265493 A1 · Aorta-specific dna methylation patterns in cell-free dna from patients with bicuspid aortic valve-associated aortopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265493 A1
- Document ID: US20230265493A1
- Status: Published application
- Kind: A1
- Application number: 18/067,247
- Filed: 2022-12-16
- Published: 2023-08-24
- Earliest claimed: 2021-12-17
- Assignees: UTI Limited Partnership
- Applicants: UTI Limited Partnership
- Inventors: Steven GREENWAY; Paul W.M. FEDAK; Ashna Karimbhai MAREDIA; Mohammad ALEINATI
- Web page: https://patentgrep.com/patent/US20230265493A1

## CPC

- C12Q 1/686: Polymerase chain reaction [PCR]
- C12Q 1/6883: for diseases caused by alterations of genetic material
- C12Q 2600/118: Prognosis of disease development
- C12Q 2600/154: Methylation markers
- G01N 2800/32: Cardiovascular disorders
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Described herein is a method of determining the risk of a human subject with congenital BAV having BAV-associated aortopathy or developing BAV-associated aortopathy, comprising: obtaining a cell free DNA (cfDNA) sample from the subject, measuring the level of methylation of a methylation marker that is associated with BAV-associated aortopathy in the cfDNA sample, optionally comparing the level of methylation of the methylation maker in the sample of the subject with a comparator control, wherein when the methylation marker is hypo- or hypermethylated the subject as being at risk of developing BAV-associated aortopathy.

## Claims

### Claim 1

A method of determining the risk of a human subject with congenital BAV having BAV-associated aortopathy or developing BAV-associated aortopathy, comprising:
obtaining a cell free DNA (cfDNA) sample from the subject,
measuring the level of methylation of a methylation marker that is associated with BAV-associated aortopathy in the cfDNA sample,
optionally comparing the level of methylation of the methylation maker in the sample of the subject with a comparator control,
wherein disproportionate hypomethylation of the methylation marker in the cfDNA sample would suggest that the subject is at risk of developing BAV-associated aortopathy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the methylation marker comprises a differentially methylated region (DMR) on Chr 11.

### Claim 3 (depends on 2)

The method of claim 2, wherein the DMR on Chr 11 comprises position Chr 11:3,168,734-3,168,832.

### Claim 4 (depends on 1)

The method of any one of claims 1, wherein the step of measuring the cfDNA for the presence of one or more methylation markers comprises sequencing the cfDNA.

### Claim 5 (depends on 4)

The method of claim 4, wherein sequencing comprises bisulfite sequencing.

### Claim 6 (depends on 5)

The method of claim 5, wherein bisulfite sequencing is carried out using a forward primer (GGGTATTTAGTTATGAGGGAATAATG; SEQ ID NO:1) and a reverse primer (CAAACCTATCTTTAATTTCCACCC; SEQ ID NO:2).

### Claim 7 (depends on 5)

The method of claim 5, wherein the sequencing comprises droplet digital PCR assay.

### Claim 8

A kit for determining the risk of a human subject with congenital BAV having BAV-associated aortopathy or developing BAV-associated aortopathy, comprising:
a forward primer (GGGTATTTAGTTATGAG-GGAATAATG; SEQ ID NO: 1) and a reverse primer (CAAACCTATCTTTAATTTCCACCC; SEQ ID NO:2), optionally a container, and optionally instructions for the use thereof.
